Nevro Corp. (NVRO)
USD 5.84
(0.0%)
USD 5.84
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 389.36 Million USD | 0.7% |
| 2022 | 375.2 Million USD | 5.11% |
| 2021 | 356.97 Million USD | 14.14% |
| 2020 | 312.75 Million USD | -14.27% |
| 2019 | 364.82 Million USD | 15.79% |
| 2018 | 315.06 Million USD | 22.46% |
| 2017 | 257.27 Million USD | 46.05% |
| 2016 | 176.15 Million USD | 69.62% |
| 2015 | 103.85 Million USD | 109.38% |
| 2014 | 49.6 Million USD | 26.6% |
| 2013 | 39.17 Million USD | 31.68% |
| 2012 | 29.75 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 88.05 Million USD | -7.34% |
| 2024 Q1 | 99.92 Million USD | 10.73% |
| 2023 Q4 | 90.24 Million USD | -5.09% |
| 2023 Q3 | 95.07 Million USD | -5.0% |
| 2023 FY | 377.83 Million USD | 0.7% |
| 2023 Q1 | 100.94 Million USD | 6.71% |
| 2023 Q2 | 100.08 Million USD | -0.86% |
| 2022 Q4 | 94.59 Million USD | 2.58% |
| 2022 Q2 | 96.52 Million USD | 5.08% |
| 2022 Q1 | 91.86 Million USD | -3.66% |
| 2022 FY | 375.2 Million USD | 5.11% |
| 2022 Q3 | 92.22 Million USD | -4.46% |
| 2021 Q2 | 85.74 Million USD | 1.11% |
| 2021 FY | 356.97 Million USD | 14.14% |
| 2021 Q3 | 91.07 Million USD | 6.21% |
| 2021 Q1 | 84.8 Million USD | 7.48% |
| 2021 Q4 | 95.34 Million USD | 4.69% |
| 2020 Q4 | 78.9 Million USD | -0.91% |
| 2020 Q3 | 79.62 Million USD | 12.77% |
| 2020 Q2 | 70.61 Million USD | -15.55% |
| 2020 FY | 312.75 Million USD | -14.27% |
| 2020 Q1 | 83.61 Million USD | -10.03% |
| 2019 Q3 | 85.92 Million USD | -5.06% |
| 2019 Q2 | 90.5 Million USD | -5.2% |
| 2019 Q1 | 95.46 Million USD | 12.63% |
| 2019 FY | 364.82 Million USD | 15.79% |
| 2019 Q4 | 92.93 Million USD | 8.16% |
| 2018 Q2 | 76.12 Million USD | -2.03% |
| 2018 Q3 | 76.48 Million USD | 0.48% |
| 2018 Q4 | 84.75 Million USD | 10.82% |
| 2018 FY | 315.06 Million USD | 22.46% |
| 2018 Q1 | 77.7 Million USD | 8.4% |
| 2017 Q2 | 63.81 Million USD | 7.39% |
| 2017 FY | 257.27 Million USD | 46.05% |
| 2017 Q4 | 71.68 Million USD | 14.96% |
| 2017 Q3 | 62.35 Million USD | -2.28% |
| 2017 Q1 | 59.41 Million USD | 7.82% |
| 2016 Q1 | 35 Million USD | 4.5% |
| 2016 Q2 | 42.48 Million USD | 21.36% |
| 2016 Q3 | 43.55 Million USD | 2.54% |
| 2016 FY | 176.15 Million USD | 69.62% |
| 2016 Q4 | 55.1 Million USD | 26.51% |
| 2015 Q4 | 33.49 Million USD | 23.41% |
| 2015 Q3 | 27.14 Million USD | 8.2% |
| 2015 Q2 | 25.08 Million USD | 38.38% |
| 2015 Q1 | 18.12 Million USD | 31.35% |
| 2015 FY | 103.85 Million USD | 109.38% |
| 2014 Q1 | 10.9 Million USD | 7.14% |
| 2014 FY | 49.6 Million USD | 26.6% |
| 2014 Q4 | 13.8 Million USD | 11.04% |
| 2014 Q3 | 12.42 Million USD | -0.29% |
| 2014 Q2 | 12.46 Million USD | 14.29% |
| 2013 Q3 | 9.09 Million USD | -11.33% |
| 2013 FY | 39.17 Million USD | 31.68% |
| 2013 Q4 | 10.17 Million USD | 11.98% |
| 2013 Q1 | 10.58 Million USD | 0.0% |
| 2013 Q2 | 10.25 Million USD | -3.14% |
| 2012 FY | 29.75 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Abbott Laboratories | 15.71 Billion USD | 97.522% |
| Allurion Technologies Inc. | 120.57 Million USD | -222.926% |
| Artivion, Inc. | 223.43 Million USD | -74.265% |
| Avanos Medical, Inc. | 375.5 Million USD | -3.693% |
| Butterfly Network, Inc. | 162.46 Million USD | -139.661% |
| Butterfly Network, Inc. | 162.46 Million USD | -139.661% |
| Bio-Rad Laboratories, Inc. | 1.04 Billion USD | 62.831% |
| Boston Scientific Corporation | 7.47 Billion USD | 94.793% |
| CONMED Corporation | 564.24 Million USD | 30.993% |
| Edwards Lifesciences Corporation | 3.09 Billion USD | 87.403% |
| Paragon 28, Inc. | 210.1 Million USD | -85.325% |
| Glaukos Corporation | 367.83 Million USD | -5.854% |
| Globus Medical, Inc. | 887.16 Million USD | 56.111% |
| Inspire Medical Systems, Inc. | 568.49 Million USD | 31.509% |
| Integer Holdings Corporation | 250.95 Million USD | -55.152% |
| Medtronic plc | 16.12 Billion USD | 97.586% |
| Myomo, Inc. | 21.41 Million USD | -1718.293% |
| Owlet, Inc. | 51.21 Million USD | -660.202% |
| Penumbra, Inc. | 590.87 Million USD | 34.103% |
| Vicarious Surgical Inc. | 80.66 Million USD | -382.692% |
| Smith & Nephew plc | 3.46 Billion USD | 88.769% |
| STERIS plc | 1.4 Billion USD | 72.195% |
| Stryker Corporation | 9.2 Billion USD | 95.772% |
| Vapotherm, Inc. | 66.02 Million USD | -489.728% |
| Zimmer Biomet Holdings, Inc. | 3.27 Billion USD | 88.115% |